Publications by authors named "Dobos G"

Background And Objectives: Patients with cutaneous lymphomas (CL) are at an increased risk of developing secondary malignancies. This study aimed to assess the frequency of association between CL and Kaposi sarcoma (KS) and to identify factors that may promote the co-occurrence of these two diseases.

Patients And Methods: On January 25, 2024, we conducted a systematic search of four electronic medical databases to identify all published cases of KS associated with CL.

View Article and Find Full Text PDF

Mycosis fungoides (MF) and Sézary syndrome (SS) are the most common subtypes of the heterogeneous group of cutaneous T-cell lymphomas (CTCL). With the expansion of the biologic treatment landscape, new treatment options have become available in recent years, most notably the C-C chemokine receptor 4 (CCR4)-directed monoclonal antibody mogamulizumab. Based on the phase III pivotal trial, mogamulizumab is recommended by the German S2k guidelines for the second-line treatment of stage IB and above SS and MF, after at least one prior systemic therapy.

View Article and Find Full Text PDF

Due to technical roadblocks, it is unclear how visual circuits represent multiple features or how behaviorally relevant representations are selected for long-term memory. Here we developed Moculus, a head-mounted virtual reality platform for mice that covers the entire visual field, and allows binocular depth perception and full visual immersion. This controllable environment, with three-dimensional (3D) corridors and 3D objects, in combination with 3D acousto-optical imaging, affords rapid visual learning and the uncovering of circuit substrates in one measurement session.

View Article and Find Full Text PDF
Article Synopsis
  • * Radiation oncologists must make tailored decisions for patient treatment, but these choices would benefit from more clinical evidence and research.
  • * The article calls for a prospective trial to better understand how different radiation doses affect patient outcomes in primary cutaneous lymphoma treatment.
View Article and Find Full Text PDF
Article Synopsis
  • Interferon-alpha is crucial for treating cutaneous T-cell lymphomas (CTCL), but the approved version (IFN-α2a) has been unavailable since January 2020, prompting the use of pegylated interferon-α2a (pegIFN-α2a), which is not officially approved for this condition.
  • A study involving 70 CTCL patients from twelve German skin centers found a 55.2% overall response rate to pegIFN-α2a, with common adverse effects leading to a 50% discontinuation rate within about 63 weeks.
  • The findings suggest that pegIFN-α2a therapy may have similar efficacy and side effects as the discontinued IF
View Article and Find Full Text PDF

In 1997 rituximab, a genetically engineered chimeric monoclonal antibody (mAb) targeting CD20 expressed on B cells was approved for treatment of non-Hodgkin's lymphoma. Since then, pharmacological improvements combined with increased knowledge on the immunopathogenesis of diseases led to the development of specific mAb targeting different antigens (e.g.

View Article and Find Full Text PDF
Article Synopsis
  • Sezary syndrome (SS) used to have very few treatment options and not a good outlook for patients, but new therapies are helping a lot.
  • In a study of 178 patients treated from 2012 to 2020, more advanced treatments led to much better survival rates: about 56% of patients lived at least 5 years.
  • Patients who had a special treatment called allogeneic stem-cell transplantation (AlloSCT) had even better chances to survive, with around 91% living for 5 years, but those who couldn't get that treatment still faced challenges.
View Article and Find Full Text PDF
Article Synopsis
  • Sézary syndrome is a rare and deadly skin cancer, and this study looked into the survival rates and factors affecting outcomes, particularly focusing on the treatment mogamulizumab.
  • *The research analyzed data from 339 patients diagnosed between 2000 and 2020 across Europe, highlighting that age over 80 and large-cell transformation worsened survival rates.
  • *Results indicated that patients treated with mogamulizumab had significantly lower mortality rates, suggesting it is an effective treatment option for Sézary syndrome.
View Article and Find Full Text PDF

Background: Ramadan fasting has seen increased attention in research, often with inconsistent findings. This study aims to investigate whether dietary and lifestyle modifications during Ramadan can improve well-being and health in healthy adult Muslims.

Method: A randomised controlled trial with two parallel groups was conducted in an outpatient clinic of a university hospital in Essen, Germany, in 2016.

View Article and Find Full Text PDF

Background: Neck reflex points or Adler-Langer points are commonly used in neural therapy to detect so-called interference fields. Chronic irritations or inflammations in the sinuses, teeth, tonsils, or ears are supposed to induce tension and tenderness of the soft tissues and short muscles in the upper cervical spine. The individual treatment strategy is based on the results of diagnostic Adler-Langer point palpation.

View Article and Find Full Text PDF

Visual virtual reality (VR) systems for head-fixed mice offer advantages over real-world studies for investigating the neural circuitry underlying behavior. However, current VR approaches do not fully cover the visual field of view of mice, do not stereoscopically illuminate the binocular zone, and leave the lab frame visible. To overcome these limitations, we developed iMRSIV (Miniature Rodent Stereo Illumination VR)-VR goggles for mice.

View Article and Find Full Text PDF

Background: Primary cutaneous lymphomas (PCL) are rare skin tumors of lymphoproliferative neoplasms and belong to the heterogeneous group of non-Hodgkin's lymphomas. PCL encompass a broad spectrum of clinical and histologic manifestations, with cutaneous T-cell lymphoma (CTCL) being the most common (73%). Due to the rarity of the diseases, population-based studies of care and epidemiology are limited.

View Article and Find Full Text PDF

Despite increasing availability of therapies, patients with Sezary syndrome (SS) commonly endure multi-line treatment journeys, mostly with partial responses of short duration. Measuring clinical benefit is challenging; time-to-next-treatment (TTNT) provides a robust, objective measurement of efficacy. This international observational study examines patterns of clinical care and therapeutic benefit as measured by TTNT.

View Article and Find Full Text PDF

Background: Efficacy and safety of mogamulizumab, a monoclonal antibody directed against C-C chemokine receptor 4, were demonstrated in a previous multinational clinical trial conducted in patients with previously treated cutaneous T-cell lymphoma (CTCL): Sézary syndrome (SS) or Mycosis Fungoides (MF).

Objectives: The real-world French OMEGA study aimed to describe effectiveness and tolerability of mogamulizumab in adult patients with CTCL, overall and according to the disease (SS or MF).

Methods: In this retrospective study, patients treated with mogamulizumab for SS or MF were included from 14 French expert centres.

View Article and Find Full Text PDF

Our research group developed a novel nano-pitted (NP) TiO surface on grade 2 titanium that showed good mechanical, osteogenic, and antibacterial properties; however, it showed weak hydrophilicity. Our objective was to develop a surface treatment method to enhance the hydrophilicity of the NP TiO surface without the destruction of the nano-topography. The effects of dilute and concentrated orthophosphoric (HPO) and nitric acids were investigated on wettability using contact angle measurement.

View Article and Find Full Text PDF

Mycosis fungoides and Sézary syndrome are epidermotropic cutaneous lymphomas, and both of them are rare diseases. Mycosis fungoides is the most frequent primary cutaneous lymphoma. In about 25% of patients with mycosis fungoides, the disease may progress to higher stages.

View Article and Find Full Text PDF